Torrent Pharmaceuticals Limited announced that the FDA has approved its ANDA for lurasidone hydrochloride oral tablets, broadening its portfolio of antipsychotic treatments. This approval is anticipated to secure competitive market positioning and drive incremental revenue gains from generic substitution in the schizophrenia sector.